![2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72a8afa13be58c968f6b234f33e37f9cd17b19f6/6-Table5-1.png)
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar
![Cancers | Free Full-Text | Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Cancers | Free Full-Text | Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA](https://pub.mdpi-res.com/cancers/cancers-12-00995/article_deploy/html/images/cancers-12-00995-g001.png?1588939545)
Cancers | Free Full-Text | Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA
![Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7fb5b65f-b95f-4179-837e-9495b3f488d1/cas12647-toc-0001-m.jpg?trick=1697162104342)
Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library
![2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72a8afa13be58c968f6b234f33e37f9cd17b19f6/5-Table4-1.png)
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Semantic Scholar
![Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients](https://www.redalyc.org/journal/3659/365968109002/2171-8695-fh-44-05-192-gt4.png)
Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients
![PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model: Molecular Therapy - Oncolytics PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/39b4dff3-f675-474d-be7f-6222f01192db/fx1_lrg.jpg)